.jpg)
STAT+: Glowing tumor-munching cells, captured on video, show the promise of a new approach to CAR-T cancer therapy
Wendell Lim stared at the video playing on his computer screen in amazement. In the…
Category: STAT+
STAT+: Pharmalittle: Pfizer Covid-19 pill could be ready by year-end; Warren urges SEC to probe Emergent CEO over stock sales
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Trillium moves ‘don’t eat me’ cancer drug into new studies, but future clouded by modest tumor responses
Trillium Therapeutics on Wednesday is announcing an expanded slate of clinical trials meant to advance…
STAT+: How one major distributor is prioritizing scarce pipette tips
Scientists across the spectrum — at universities, at public health labs, at biotechs — are…
Opinion: STAT+: Investment in antimicrobials was up in 2020, but much work remains
The emergence of the Covid-19 pandemic generated renewed interest in the development of vaccines and…
STAT+: Flagship-backed fertility company Ohana Biosciences shutters, lays off most employees
Flagship Pioneering-backed fertility company Ohana Biosciences is winding down. Employees were told Tuesday during an…
STAT+: Will India issue sidestep patents on a pair of pricey — but lifesaving — TB drugs?
A widely anticipated court hearing will be held in India on Wednesday over the cost…
.jpg)
STAT+: Eli Lilly’s earnings fall short after stock’s dramatic run
Eli Lilly posted earnings Tuesday that surprised and disappointed investors, as both sales and profit…
STAT+: Pharmalittle: What will Biden say about drug pricing? U.S. trade rep meets with drug makers over WTO proposal
Rise and shine, folks, another busy day is on the way. We can tell because,…
Opinion: STAT+: More pharma companies should make the move toward B Corps sustainability
The gradual global shift towards sustainability, with an increased focus on climate change and environmental…
STAT+: Drug pricing déjà vu: Now it’s Democrats struggling to unite on the issue
WASHINGTON — It’s the eve of a major speech by the president, and it’s anyone’s…
STAT+: Thanks to its Covid-19 response, pharma’s reputation among patient groups is climbing
Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe…
STAT+: U.K. lawmakers want Boris Johnson to disclose emails with pharma about a WTO proposal on Covid-19 vaccines
Two dozen U.K. lawmakers called on the government to publish all communications with drug makers…
STAT+: Down and out Down Under? Bristol Myers fights an ‘unreasonable’ Australian law over patents
Two big drug makers are challenging a provision in Australian patent law that they argue…
STAT+: Pharmalittle: Emergent CEO sold stock before vaccine contamination was reported; Biden urged to support WTO proposal
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The field is exploding, but microbiome therapeutics still face a wave of challenges
Even as drug makers are poised to introduce actual medicines to change a person’s microbiome…
STAT+: The FDA will this week decide whether to ban menthol cigarettes — but most likely, the fight is just getting started
WASHINGTON — The Food and Drug Administration will decide this week whether to ban menthol…
STAT+: The price of a Vertex cystic fibrosis treatment stirs anger in Australia
The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals (VRTX)…
STAT+: Accolade to acquire PlushCare as telehealth competition intensifies
In a bid to beef up the services it can provide directly to customers, Accolade…
STAT+: New data point to benefits of Bristol’s novel psoriasis pill, but safety issues will be scrutinized
Last November and then again in February, Bristol Myers Squibb said its oral drug designed…
STAT+: Pharmalittle: CDC committee to vote on J&J Covid-19 vaccine; has the White House written off the J&J shot?
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘There are no alternatives’: As Pfizer discontinues an old glaucoma drug, a small group of patients struggles to cope
Next month, an eye drop that Carol Vaghar has taken for the past few years…
STAT+: Pharmalittle: Europe looks to sue AstraZeneca over Covid-19 vaccine shortfalls; FDA skewers Emergent vaccine facility
Hello, everyone, and how are you today? Cold winds are whipping about the Pharmalot campus,…
STAT+: With $12 million in new funding, data-syncing platform Seqster takes aim at health records
If health tech challenges were mountains, patient medical records would be a kind of Everest,…
STAT+: Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
When Bluebird Bio secured European approval for its gene therapy to treat beta thalassemia in…
STAT+: More surveillance is coming to the operating room. Surgeons warn that’s risky
Much of what happens in the operating room is shrouded in mystery: The patient goes…
STAT+: Worried drug pricing reform might be left behind, Democrat pushes Biden to make clear his support
WASHINGTON — At least one Democratic lawmaker is openly pushing President Biden to include drug…
STAT+: FDA issues scathing report of Emergent plant responsible for contaminated Covid-19 vaccines
The Food and Drug Administration issued a scathing inspection report of the Emergent BioSolutions (EBS)…
STAT+: Pharmalittle: Pfizer identifies first counterfeit versions of its Covid-19 vaccine; top house Democrats investigate Emergent BioSolutions
Rise and shine, everyone, another busy day is on the way. This is the middle…
STAT+: Why hospitals hate Bernie Sanders’ latest health reform push
WASHINGTON — Progressives in Congress, led by Sen. Bernie Sanders, have ramped up pressure on…
STAT+: Congress probes Emergent’s ties to a key Trump official in wake of Covid-19 vaccine scandal
A pair of top House Democrats is investigating whether Emergent BioSolutions (EBS), which was responsible…
STAT+: Pfizer shareholders are urged to reject political spending that contradicts ‘company values’
Arguing that Pfizer’s political spending conflicts with the company’s publicly stated values, a philanthropic organization…
STAT+: Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation
Right now, trillions of donut-shaped red blood cells are whizzing through your arteries, ferrying oxygen…
STAT+: Pharmalittle: Biden aides met with U.S. health companies about supply chains; J&J Covid-19 shot notched $100m in sales
Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping…
STAT+: Genetically targeted drug from Syndax Pharma shows remissions in leukemia patients
Syndax Pharmaceuticals said Tuesday that its genetically targeted cancer drug induced complete remissions in patients…
STAT+: The future of voice tech in medicine is here. Can reality live up to the promise?
Microsoft’s high-profile of acquisition of Nuance Communications is a seeming win for patients and providers….
STAT+: Biden officials met privately with 3M, AmerisourceBergen, PhRMA and more to debate shoring up the national stockpile
WASHINGTON — The Biden administration met privately this month with some of the nation’s biggest…
STAT+: Adagio raises $336 million to advance Covid-19 antibody treatment
Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding…
STAT+: Pharmalittle: J&J denies design of its Covid-19 shot may explain blood clots; second trial against opioid makers begins
Good morning, everyone, and welcome to another working week. Once again, another delightful weekend respite…
STAT+: Advocacy groups outraged after PBM offers a $500 gift card to persuade patients to switch drugs
Dozens of patient advocacy groups are angry over an unusual move by a pharmacy benefits…
Opinion: STAT+: The FDA should embrace remote and automated drug inspection technology
While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections…
STAT+: The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry
WASHINGTON — Tom Nickels helped build the American Hospital Association into one of the biggest…
STAT+: Pharmalittle: J&J rivals rebuff bid to jointly study Covid-19 vaccine risks; will next-gen Covid shots be better or worse?
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: Developers of microbiome-based drugs face challenges. There are ways to overcome them
Manipulating the human microbiome appears to be an effective approach for treating a range of…
STAT+: A drug maker sues a medical journal, its editor, and several authors for libel
In an unusual move, Pacira Biosciences (PCRX) has filed a libel lawsuit against a medical…
STAT+: Thermo Fisher buys contract-research company PPD for $17.4 billion
Thermo Fisher Scientific announced Thursday that it will buy PPD, a contract-research company for the…
STAT+: Hints emerge about a key Senate committee’s plans for health care
WASHINGTON — A Senate hearing Thursday provided one of the clearest roadmaps to date for…
STAT+: WTO head urges movement on controversial Covid-19 vaccine proposal, but objections remain
Amid mounting pressure to widen global access to Covid-19 vaccines, the head of the World…
STAT+: In a sharp rebuke, health officials toss Trump-era proposal to exempt medical AI tools from review
In a searing rebuke, the Biden administration is formally withdrawing a last-minute proposal by the…
STAT+: Pharmalittle: Pause for J&J Covid-19 shot to continue at least a week; Biden expands candidate list for FDA commish
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…